Research And Markets Research And Markets
0 CHECKOUT

The Pharmaceutical Market: UK

  • ID: 45446
  • May 2012
  • Region: United Kingdom, Great Britain
  • 112 Pages
  • Espicom Business Intelligence Ltd
1 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Novartis
  • Pfizer Ltd.
  • ProStrakan
  • MORE

These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

Executive Summary

THE PHARMACEUTICAL MARKET: UK - REVIEW

The UK pharmaceutical market is set to experience moderate growth over the coming years, tempered slightly by the effects of the economic recession. Deep public spending cuts are underway, with health expenditure experiencing very limited growth over the next few years, of just 0.4% in real terms up to 2015. In addition, the NHS must make a total of £20.0 billion (US$31.3 billion) in annual efficiency and productivity savings up to 2014. Tighter NHS spending could impact negatively on the market, as it will READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Novartis
  • Pfizer Ltd.
  • ProStrakan
  • MORE

HEALTHCARE STATISTICS

A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.

EXECUTIVE SUMMARY
Including Espicom's at a glance strategic analysis and key data projections

MACROENVIRONMENT
Political, economic, legal and demographic analysis

EPIDEMIOLOGY
Disease burden and prevalence

HEALTHCARE
Organisation, expenditure, infrastructure, services and workforce

REGULATORY AFFAIRS
Regulatory developments and marketing registration/authorisation

PRICING & REIMBURSEMENT

DISTRIBUTION CHANNELS

MARKET ANALYSIS
Projections, product development, manufacturing and trade

COMPETITION
Trade associations, trade fairs, company intelligence and competitive strategies

OTC PHARMACEUTICALS

GENERIC PHARMACEUTICALS

BIOLOGICS & BIOSIMILARS

OPPORTUNITIES & CHALLENGES
Espicom's unique strategic analysis

DIRECTORY

METHODOLOGY & SOURCES

Note: Product cover images may vary from those shown
3 of 4

- AstraZeneca
- Eli Lilly and Company
- GlaxoSmithKline
- Novartis
- Pfizer Ltd.
- ProStrakan
- Shire Pharmaceuticals Group Plc.
- Wyeth

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

RELATED PRODUCTS from Db